WARD Susan J
Recognizing the urgency of finding new approaches to clinical trial design and analysis in rare disease, in 2015 Dr. Ward founded the collaborative Trajectory Analysis Project (cTAP), a dynamic pan-stakeholder alliance applying advanced data science to the largest collection of patient clinical data in Duchenne Muscular Dystrophy http://ctap-duchenne.org
A pharmaceutical executive, scientist, consultant and educator whose career is marked by innovation in solving tough cross-disciplinary challenges. Dr. Ward was a prominent pain researcher before joining Wyeth (now Pfizer) where she became the first woman in the industry to head R&D in the U.K.. A member of the Wyeth global executive team, she pioneered project management in drug discovery, halving time to initiate clinical trials, and subsequently oversaw development and world-wide approval of innovative products including Enbrel, Rapamune, and the first toxin-antibody conjugates developed in cancer. As an officer of Millennium Pharmaceuticals (now Takeda) from 2000, Dr. Ward led strategy, productivity and the technology platform, with annual revenue exceeding M. As a consultant, she developed Alnylam’s research strategy, introduced a pioneering quality-based productivity platform at Novartis, and served as a business advisor to innovative technology companies.
Dr Ward is a member of the MGH-Harvard Rare Disease Think Tank, is an experienced independent board director of emerging Biotech, and served for 6 years as a Trustee and Finance Chair of the Cambridge School of Weston, a leader in progressive education. Dr. Ward earned her Ph.D. from the University of Manchester, UK, has authored over 60 articles in peer-reviewed journals, and holds 9 patents.
